Table 1. Sensitivity of SEPT9 methylation assay in early stage colorectal cancer.

Study	Year	Country	Type of study	Kit used	Algorithm	Polyps	Adenoma	Stage I	Stage II
Ahlquist et al. (43)	2012	USA	Case-control	Epipro colon 1.0	1/3	–	13.6% (3/22)	57.1% (4/7)	57.1% (4/7)
Church et al. (44)	2014	USA, Germany	Prospective	Epipro colon 1.0	1/2	–	8.8% (46/523)	36.4% (8/22)	57.1% (8/14)
Ding et al. (45)	2015	China	Case-control	Epipro colon 2.0	2/3	–	–	50.0% (1/2)	53.3% (16/30)
deVos et al. (46)	2009	Germany	Case-control	Epipro colon 1.0	1/3	–	–	52.6% (10/19)	75.0% (30/40)
					2/3			26.3% (5/19)	60.0% (24/40)
Grützmann et al. (47)	2008	Germany	Case-control	Research assay	2/3	11.8% (6/51)	–	50.0% (11/22)	69.4% (25/36)
He et al. (48)	2014	China	Case-control	Epipro colon 2.0	2/3	–	–	35.7% (5/14)	81.0% (17/21)
Jin et al. (49)	2015	China	Case-control	Epipro colon 2.0	2/3	20.7% (35/169)	27.4% (23/84)	66.7% (12/18)	82.6% (19/23)
Johnson et al. (50)	2014	USA	Prospective	Epipro colon 1.0	1/3	–	–	61.5% (16/26)	80.0% (16/20)
Kang et al. (51)	2014	China	Case-control	Epipro colon 2.0	2/3	–	–	48.0% (12/25)	82.6% (19/23)
Li et al. (52)	2015	China	Case-control	Epipro colon 2.0	1/1	–	–	40.0% (2/5)	65.5% (19/29)
Lofton-Day et al. (53)	2008	USA	Case-control	Research assay	1/1	–	–	30.0% (6/20)	56.3% (18/32)
Ørntoft et al. (54)	2015	Denmark	Case-control	Epipro colon 2.0	1/3	–	14.3% (3/21)	37.1% (13/35)	91.4% (32/35)
					2/3		0% (0/21)	17.1% (6/35)	74.3% (26/35)
Song et al. (55)	2016	China	Case-control	Epipro colon 2.0	1/3	26.4% (23/87)	37.2% (42/113)	64.3% (27/42)	87.6% (92/105)
					2/3	9.2% (8/87)	26.5% (30/113)	54.8% (23/42)	82.9% (87/105)
Tóth et al. (56)	2012	Hungary	Case-control	Epipro colon 2.0	1/3	–	–	84.0% (21/25)	100.0% (14/14)
					2/3			60.0% (15/25)	92.9% (13/14)
Warren et al. (57)	2011	USA, Russia	Case-control	Epipro colon 1.0	1/3	–	–	71.4% (5/7)	90.3% (28/31)
Wu et al. (58)	2016	China	Case-control	Research assay	1/1	5.2% (6/116)	9.8% (21/214)	64.9% (24/37)	72.7% (48/66)